Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-Pilot: ABT-450/r + ABT-333 + RBV in HCV GT1
NCT01306617Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2011
- Primary completion
- Nov 2011
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of paritaprevir and dasabuvir in hepatitis C (HCV) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) at Week 12. Started Feb 2011; status: completed.
02
Drugs
paritaprevirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01306617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306617.